kabutan

Daito Pharma, First Half Ordinary Profit Increases by 20%, Sep-Nov Ordinary Profit Increases by 46%

Wed Jan 14, 2026 3:30 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on January 14th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending May 2026 (June to November) increased 20.0% from the same period last year, reaching 1.76 billion yen. Progress toward the full-year plan of 3.00 billion yen was 58.8%, almost the same as the five-year average of 56.9%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the December to May period (second half) is expected to nearly flat at 1.23 billion yen, up 0.1% from the same period last year.

In the most recent three-month period, from September to November (2Q), the consolidated ordinary profit increased 46.2% from the same period last year, reaching 0.71 billion yen. However, the operating profit margin remained almost flat, changing from 5.2% in the same period last year to 5.2%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jun - Nov, 2023 24,110 2,289 2,314 1,552 49.1 59.0 Jan 12, 2024 J-GAAP
Jun - Nov, 2024 24,584 1,471 1,470 908 29.7 54.3 Jan 10, 2025 J-GAAP
Jun - Nov, 2025 25,141 1,627 1,764 1,233 41.3 58.8 Jan 14, 2026 J-GAAP
YoY +2.3% +10.6% +20.0% +35.8% +39.1%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jun - Nov, 2025 Guidance ー ー ー ー － 20 Jul 11, 2025 J-GAAP
Jun - Nov, 2025 Results 25,141 1,627 1,764 1,233 41.3 20 Jan 14, 2026 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2024 26,059 1,148 1,235 1,000 32.9 17.50 Jul 11, 2025 J-GAAP
Dec - May, 2025 Guidance 27,359 1,373 1,236 1,067 36.2 20 Jan 14, 2026 J-GAAP
YoY +5.0% +19.6% +0.1% +6.7% +10.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 50,643 2,619 2,705 1,908 62.7 35 Jul 11, 2025 J-GAAP
May, 2026 Guidance 52,500 3,000 3,000 2,300 78.1 40 Jul 11, 2025 J-GAAP
YoY +3.7% +14.5% +10.9% +20.5% +24.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Sep - Nov, 2024 11,906 622 487 290 9.5 5.2 Jan 10, 2025 J-GAAP
Dec - Feb, 2024 12,025 398 563 309 10.1 3.3 Apr 14, 2025 J-GAAP
Mar - May, 2025 14,034 750 672 691 22.7 5.3 Jul 11, 2025 J-GAAP
Jun - Aug, 2025 13,011 998 1,052 696 23.2 7.7 Oct 10, 2025 J-GAAP
Sep - Nov, 2025 12,130 629 712 537 18.0 5.2 Jan 14, 2026 J-GAAP
YoY +1.9% +1.1% +46.2% +85.2% +89.7%

Related Articles